148: Why Neuropathy Isn’t Just About Blood Sugar

Bikman highlights a human study where patients with neuropathy associated with impaired glucose tolerance (pre-diabetes) undertook a one-year lifestyle intervention based on the Diabetes Prevention Program. Skin biopsies showed cutaneous reinnervation, meaning nerve fibers regrew. This is a direct demonstration that improving insulin sensitivity and metabolic health can reverse nerve damage, independent of glucose lowering alone. He emphasizes that the same interventions that address insulin resistance—carbohydrate restriction, fasting, exercise, sleep—are the ones that also lower glucose and stabilize variability, thus attacking all three pillars simultaneously.

Bikman positions carbohydrate control as the foundational dietary lever. He argues that because peripheral nerves take up glucose independently of insulin, high carbohydrate intake causes glucose flooding and activation of the sorbitol pathway and glycation. Simultaneously, high insulin levels driven by carbohydrates worsen insulin resistance in Schwann cells. By limiting carbs, you reduce both the glucose load and the insulin burden, allowing nerves to recover.

Bikman mentions fasting as a method to stabilize blood glucose and enhance insulin sensitivity. He ties it to the three-pillar framework: fasting reduces both average glucose and glycemic variability, and by lowering chronic insulin, it helps reverse insulin resistance at the Schwann cell level. He does not detail specific protocols, but this advice is consistent with the lifestyle intervention that produced nerve regrowth.

Bikman emphasizes resistance exercise over general activity because building muscle increases the body's glucose disposal capacity. He states that exercise, especially resistance exercise, helps muscles, which are a major site of insulin resistance. Improved muscle insulin sensitivity reduces post-meal glucose spikes and lowers circulating insulin, thereby benefiting the nerve.

Bikman includes sleep as part of the comprehensive approach, noting that better sleep habits are part of improving metabolism. He doesn't elaborate extensively, but connects it to the overall strategy to enhance insulin sensitivity and stabilize glucose. It is the fourth point in his closing recommendations.

Bikman argues that the nerve is hit from three directions. First, chronic hyperglycemia floods the nerve with glucose via insulin-independent transporters, triggering the sorbitol pathway and glycation damage. Second, insulin resistance starves Schwann cells of the trophic insulin signal they need to maintain myelin, causing nerve degeneration even without high glucose. Third, glycemic variability—the spikes and crashes seen in a day—imposes repeated oxidative stress that a steady average glucose does not capture. This three-pillar framework explains why pre-diabetics can have neuropathy with normal A1C, why Type 2 diabetes patients don't benefit as much from glucose control, and why metabolic syndrome components independently predict nerve damage. Evidence includes genetic deletion of insulin receptors in mouse Schwann cells causing neuropathy with normal glucose, human studies showing MAGE predicts neuropathy beyond A1C, and a lifestyle intervention study where pre-diabetics regrew nerve fibers on skin biopsy after improving insulin sensitivity.

Bikman explains that each upward glucose excursion provokes a burst of reactive oxygen species via the NADPH oxidase pathway, overwhelming the nerve's antioxidant capacity. Contrary to sustained high glucose, intermittent spikes don't let the nerve acclimate, causing repeated insults. Human studies validate this: in type 2 diabetics with A1C below 7%, higher MAGE independently predicted peripheral neuropathy. Nerve conduction studies found reduced action potential amplitude with higher MAGE. Even long-term A1C variability predicts incident painful neuropathy. Therefore, time-in-range (70–low 100s mg/dL) and minimal excursions may be as protective as average glucose. Bikman concludes that CGM-derived metrics like time in tight range are where the action really is for nerve protection.

Bikman details that Schwann cells, the glial cells wrapping peripheral axons to form myelin, require insulin signaling to synthesize the lipids needed for that myelin. Under physiological conditions, insulin activates these receptors to promote fatty acid and cholesterol synthesis, maintaining the nerve's myelin sheath. In a mouse model where both insulin and IGF-1 receptors were genetically deleted from Schwann cells, the mice developed sensory neuropathy with reduced myelin and altered nerve function, despite normal glucose levels. This demonstrates that insulin signaling loss alone is sufficient to cause neuropathy. In humans with insulin resistance, Schwann cells become resistant to insulin just like muscle and liver, but in the context of high circulating insulin and lipotoxicity, they also accumulate harmful lipids instead of beneficial ones. So the nerve suffers both from lack of trophic support and from toxic lipid exposure. This explains why obese, insulin-resistant individuals develop neuropathy before meeting diabetes criteria, and why a lifestyle intervention that restored insulin sensitivity in pre-diabetics led to measurable nerve fiber regrowth on skin biopsy.